CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 257 enrolled
Drug / intervention
APD405 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00895830
NCT00895830Phase 2Completed

Randomised, Double-blind, Placebo-controlled, Phase II Study to Assess the Safety and Efficacy of Different Doses of Intravenous APD405 for the Prevention of Post-operative Nausea and Vomiting

Acacia Pharma Ltd·interventional·Posted May 8, 2009·Updated Mar 29, 2011

In Brief

A Phase 2 clinical trial evaluating APD405 and Placebo for Postoperative Nausea and Vomiting. Completed, enrolled 257 participants across 18 sites in 4 countries.

Detailed Summary

To assess the efficacy and safety of different doses of APD405 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Switzerland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 8, 2009
Enrollment StartMay 1, 2009
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.2 years ago

Interventions

APD405drug

IV

Placebodrug

IV